Interleukin‐1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis
暂无分享,去创建一个
R. Codoceo | C. Fernández‐Capitán | F. Arnalich | C. Capiscol | C. Montiel | D. López-Maderuelo | J. López | R. Madero | Julia López | L. M. Solís-Garrido | L. M. Solís-Garrido
[1] N. Camp,et al. Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians , 2001, Gut.
[2] J. Renart,et al. Greater diversity than previously thought of chromaffin cell Ca2+ channels, derived from mRNA identification studies , 2000, FEBS letters.
[3] J. Renart,et al. Predictive Value of Nuclear Factor κB Activity and Plasma Cytokine Levels in Patients with Sepsis , 2000, Infection and Immunity.
[4] J. Dhainaut,et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. , 1999, JAMA.
[5] A. Hoeft,et al. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. , 1999, Critical care medicine.
[6] M. Hurme,et al. Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. , 1998, Annals of medicine.
[7] M. Hurme,et al. IL‐1 receptor antagonist (IL‐1Ra) plasma levels are co‐ordinately regulated by both IL‐1Ra and IL‐1β genes , 1998 .
[8] C. Dinarello,et al. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. , 1997, Chest.
[9] S. Hollerbach,et al. Imbalance of the interleukin 1 system in colonic mucosa—association with intestinal inflammation and interleukin 1 receptor agonist genotype 2 , 1997 .
[10] S. Endres,et al. Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis. , 1997, Gut.
[11] F. Stüber,et al. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. , 1996, Critical care medicine.
[12] D. Grennan,et al. Cytokine production by normal human monocytes: inter‐subject variation and relationship to an IL‐1 receptor antagonist (IL‐1Ra) gene polymorphism , 1995, Clinical and experimental immunology.
[13] Á. Hernanz,et al. Cell-mediated immune response and cytokine production in idiopathic senile anorexia , 1994, Mechanisms of Ageing and Development.
[14] C. Gordon,et al. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. , 1994, Arthritis and rheumatism.
[15] A. Blakemore,et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat , 1993, Human Genetics.
[16] W. Knaus,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.
[17] E. Draper,et al. APACHE II: A severity of disease classification system , 1985, Critical care medicine.
[18] S. V. Deventer,et al. Cytokine and cytokine receptor polymorphisms in infectious disease , 2000, Intensive Care Medicine.
[19] A. Hill,et al. The immunogenetics of human infectious diseases. , 1998, Annual review of immunology.
[20] B. Taylor,et al. Prediction of outcome from intensive care: a prospective cohort study comparing Acute Physiology and Chronic Health Evaluation II and III prognostic systems in a United Kingdom intensive care unit. , 1997, Critical care medicine.
[21] D. Grennan,et al. Lack of association between an interleukin-1 receptor antagonist gene polymorphism and systemic lupus erythematosus. , 1995, Disease markers.